Suppression of Plasma Androgens by Spironolactone in Castrated Men with Carcinoma of the Prostate
- 1 August 1975
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 114 (2) , 254-256
- https://doi.org/10.1016/s0022-5347(17)67001-0
Abstract
Spironolactone, an inhibitor of androgen synthesis, has been administered to castrated men with metastatic carcinoma of the prostate. Plasma levels of testosterone, androstenedione and dehydroepiandrosterone were significantly decreased. These data indicate that spironolactone suppresses adrenal androgen production and suggest that it may be of benefit in the treatment of orchiectomized patients with advanced carcinoma of the prostate.Keywords
This publication has 13 references indexed in Scilit:
- Antiandrogenic Effect of Spironolactone in RatsJournal of Urology, 1974
- Plasma Testosterone: An Accurate Monitor of Hormone Treatment in Prostatic CancerBritish Journal of Urology, 1973
- Experience in the Treatment of Prostatic Carcinoma with Cyproterone AcetateJournal of Urology, 1973
- Adrenal androgens in manThe American Journal of Medicine, 1972
- Anti-androgenic activity of spironolactoneSteroids, 1969
- Aldosteronism in HypertensionAnnals of Internal Medicine, 1968
- Plasma Testosterone Levels in Patients with Prostatic Carcinoma Before and after TreatmentJournal of Urology, 1968
- Spironolactone Therapy and GynecomastiaJAMA, 1965
- The Effect of Anti-Androgens on the Response of Rat Preputial Glands to Testosterone*Journal of Investigative Dermatology, 1964
- Studies on Prostatic Cancer. V. Excretion of 17-Ketosteroids, Estrogens and Gonadotropins before and after Castration1Journal of Clinical Endocrinology & Metabolism, 1942